Sopharma AD (WSE:SPH)
7.30
-0.20 (-2.67%)
Mar 16, 2026, 4:49 PM CET
Sopharma AD Income Statement
Financials in millions BGN. Fiscal year is January - December.
Millions BGN. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,610 | 2,121 | 1,875 | 1,663 | 1,603 |
Other Revenue | 22.89 | 18.57 | 13.53 | 8.5 | 8.04 |
Revenue | 2,633 | 2,139 | 1,889 | 1,672 | 1,611 |
Revenue Growth (YoY) | 23.05% | 13.27% | 13.00% | 3.73% | 11.43% |
Cost of Revenue | 2,002 | 1,675 | 1,470 | 1,306 | 1,264 |
Gross Profit | 631.15 | 464.42 | 418.52 | 365.37 | 346.96 |
Selling, General & Admin | 397.32 | 306.58 | 251.19 | 215.55 | 221.99 |
Other Operating Expenses | 19.87 | 20 | 18 | 11.76 | 7.3 |
Operating Expenses | 496.28 | 388.14 | 325.22 | 279.51 | 285.48 |
Operating Income | 134.86 | 76.28 | 93.31 | 85.86 | 61.48 |
Interest Expense | -21.5 | -12.87 | -10.98 | -6.02 | -10.79 |
Interest & Investment Income | 4.06 | 2.94 | 3.42 | 3.19 | 4.87 |
Earnings From Equity Investments | 38.33 | 25.72 | 24.47 | 22.64 | 12.09 |
Currency Exchange Gain (Loss) | -0.94 | -5.76 | -1.39 | -0.13 | 2.29 |
Other Non Operating Income (Expenses) | -1.07 | 2.41 | -2.55 | -3.19 | -0.94 |
EBT Excluding Unusual Items | 153.75 | 88.72 | 106.28 | 102.35 | 69 |
Impairment of Goodwill | - | - | - | -9.6 | - |
Gain (Loss) on Sale of Investments | - | 0.1 | 0.95 | -1.59 | 0.15 |
Gain (Loss) on Sale of Assets | 0.51 | 1.33 | 4.53 | 1.95 | 38.01 |
Asset Writedown | -0.07 | -0.42 | -1.44 | -8.46 | -10.34 |
Other Unusual Items | 3.06 | 1.73 | 0.87 | 0.43 | 0.75 |
Pretax Income | 157.24 | 91.46 | 111.2 | 85.08 | 97.57 |
Income Tax Expense | 15.66 | 9.07 | 11.32 | 8.74 | 5.87 |
Earnings From Continuing Operations | 141.58 | 82.4 | 99.87 | 76.33 | 91.7 |
Minority Interest in Earnings | -8.06 | -4.55 | -3.9 | -5.21 | -2.21 |
Net Income | 133.52 | 77.85 | 95.98 | 71.12 | 89.5 |
Net Income to Common | 133.52 | 77.85 | 95.98 | 71.12 | 89.5 |
Net Income Growth | 71.52% | -18.89% | 34.95% | -20.53% | 200.27% |
Shares Outstanding (Basic) | 343 | 493 | 392 | 364 | 376 |
Shares Outstanding (Diluted) | 343 | 494 | 415 | 375 | 376 |
Shares Change (YoY) | -30.63% | 19.22% | 10.64% | -0.36% | -0.31% |
EPS (Basic) | 0.39 | 0.16 | 0.24 | 0.20 | 0.24 |
EPS (Diluted) | 0.39 | 0.16 | 0.23 | 0.19 | 0.24 |
EPS Growth | 148.52% | -31.87% | 21.05% | -19.73% | 199.61% |
Free Cash Flow | -26.45 | 43.25 | 20.64 | 90.74 | -96.31 |
Free Cash Flow Per Share | -0.08 | 0.09 | 0.05 | 0.24 | -0.26 |
Dividend Per Share | - | 0.052 | 0.330 | 0.200 | - |
Dividend Growth | - | -84.33% | 65.00% | - | - |
Gross Margin | 23.97% | 21.71% | 22.16% | 21.86% | 21.53% |
Operating Margin | 5.12% | 3.56% | 4.94% | 5.14% | 3.82% |
Profit Margin | 5.07% | 3.64% | 5.08% | 4.25% | 5.55% |
Free Cash Flow Margin | -1.00% | 2.02% | 1.09% | 5.43% | -5.98% |
EBITDA | 214.02 | 112.85 | 127.86 | 118.97 | 93.85 |
EBITDA Margin | 8.13% | 5.27% | 6.77% | 7.12% | 5.82% |
D&A For EBITDA | 79.15 | 36.57 | 34.56 | 33.11 | 32.37 |
EBIT | 134.86 | 76.28 | 93.31 | 85.86 | 61.48 |
EBIT Margin | 5.12% | 3.56% | 4.94% | 5.14% | 3.82% |
Effective Tax Rate | 9.96% | 9.91% | 10.18% | 10.28% | 6.02% |
Advertising Expenses | 1.87 | 1.98 | 2.27 | 22.06 | 27.41 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.